Eli Lilly And Co (NYSE: LLY) traded higher Tuesday after the company announced it will supply 614,000 additional doses of bamlanivimab with etesevimab to the U.S. government for a total of $1.29 billion.
Eli Lilly expects that the additional doses will increase revenue by $840 million and earnings by approximately 25 cents per share beyond the guidance that was issued during its most recent financial results.
Bamlanivimab can be administered with etesevimab for treatment or post-exposure prevention of COVID-19. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals.
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology and immunology.
See Also: Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients
LLY Price Action: Eli Lilly has traded as high as $275.87 and as low as $129.21 over a 52-week period.
The stock was up 2.83% at $256.36 at time of publication.
Photo: Paul Sableman from Flickr.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
